Kyle Rove
Concepts (306)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urologic Surgical Procedures | 15 | 2026 | 126 | 6.580 |
Why?
| | Prostatic Neoplasms | 17 | 2014 | 972 | 2.800 |
Why?
| | Urinary Bladder | 6 | 2026 | 194 | 2.730 |
Why?
| | Urinary Bladder, Neurogenic | 4 | 2026 | 46 | 2.320 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2026 | 344 | 2.020 |
Why?
| | Androgen Antagonists | 5 | 2014 | 91 | 1.780 |
Why?
| | Analgesics, Opioid | 10 | 2026 | 1221 | 1.750 |
Why?
| | Abdominal Neoplasms | 2 | 2025 | 48 | 1.720 |
Why?
| | Urology | 5 | 2024 | 63 | 1.620 |
Why?
| | Perioperative Care | 3 | 2024 | 235 | 1.590 |
Why?
| | Postoperative Complications | 11 | 2026 | 3034 | 1.520 |
Why?
| | Urodynamics | 5 | 2025 | 44 | 1.480 |
Why?
| | Length of Stay | 10 | 2026 | 1358 | 1.350 |
Why?
| | Child | 40 | 2026 | 22693 | 1.160 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2026 | 640 | 1.140 |
Why?
| | Acute Kidney Injury | 2 | 2026 | 866 | 1.020 |
Why?
| | Spinal Dysraphism | 4 | 2025 | 113 | 1.010 |
Why?
| | Testosterone | 5 | 2015 | 419 | 0.980 |
Why?
| | Ketorolac | 1 | 2026 | 33 | 0.950 |
Why?
| | Ibuprofen | 1 | 2026 | 87 | 0.930 |
Why?
| | Child, Preschool | 19 | 2026 | 11913 | 0.900 |
Why?
| | Negative-Pressure Wound Therapy | 1 | 2025 | 29 | 0.860 |
Why?
| | Urinary Bladder Neoplasms | 3 | 2017 | 259 | 0.850 |
Why?
| | Ileum | 1 | 2025 | 112 | 0.850 |
Why?
| | Testicular Neoplasms | 2 | 2016 | 108 | 0.850 |
Why?
| | Pediatrics | 4 | 2026 | 1124 | 0.830 |
Why?
| | Metabolic Diseases | 1 | 2025 | 114 | 0.820 |
Why?
| | Prospective Studies | 16 | 2026 | 8123 | 0.810 |
Why?
| | Kidney Calculi | 4 | 2025 | 43 | 0.800 |
Why?
| | Neuroblastoma | 1 | 2025 | 177 | 0.800 |
Why?
| | Specialties, Surgical | 1 | 2025 | 88 | 0.790 |
Why?
| | Practice Patterns, Physicians' | 3 | 2024 | 1408 | 0.790 |
Why?
| | Neoplasms, Hormone-Dependent | 2 | 2014 | 33 | 0.790 |
Why?
| | Physicians, Women | 1 | 2025 | 92 | 0.780 |
Why?
| | Robotic Surgical Procedures | 1 | 2026 | 210 | 0.760 |
Why?
| | Urinary Bladder Diseases | 1 | 2022 | 18 | 0.740 |
Why?
| | Surgeons | 2 | 2025 | 351 | 0.740 |
Why?
| | Drug Prescriptions | 1 | 2024 | 314 | 0.720 |
Why?
| | Ureter | 1 | 2022 | 37 | 0.720 |
Why?
| | Delphi Technique | 1 | 2024 | 350 | 0.710 |
Why?
| | Propensity Score | 1 | 2024 | 376 | 0.710 |
Why?
| | Lower Urinary Tract Symptoms | 2 | 2025 | 62 | 0.710 |
Why?
| | Male | 47 | 2026 | 73396 | 0.700 |
Why?
| | Humans | 71 | 2026 | 146342 | 0.700 |
Why?
| | Gonadotropin-Releasing Hormone | 3 | 2014 | 215 | 0.700 |
Why?
| | Surgical Wound Infection | 1 | 2025 | 349 | 0.670 |
Why?
| | Postoperative Nausea and Vomiting | 1 | 2020 | 23 | 0.650 |
Why?
| | Urologic Diseases | 2 | 2018 | 44 | 0.650 |
Why?
| | Analgesia | 1 | 2020 | 106 | 0.600 |
Why?
| | Adolescent | 21 | 2026 | 22557 | 0.580 |
Why?
| | Hyperoxaluria, Primary | 3 | 2023 | 14 | 0.570 |
Why?
| | Wolfram Syndrome | 1 | 2018 | 5 | 0.550 |
Why?
| | Pons | 1 | 2018 | 33 | 0.540 |
Why?
| | Urination | 1 | 2018 | 46 | 0.530 |
Why?
| | Bone Neoplasms | 2 | 2011 | 272 | 0.530 |
Why?
| | Prostate-Specific Antigen | 4 | 2014 | 162 | 0.520 |
Why?
| | Electronic Health Records | 2 | 2025 | 1210 | 0.500 |
Why?
| | Ureteroscopy | 3 | 2025 | 16 | 0.500 |
Why?
| | Recovery of Function | 2 | 2018 | 725 | 0.490 |
Why?
| | Sertoli-Leydig Cell Tumor | 1 | 2016 | 8 | 0.490 |
Why?
| | Cystoscopy | 1 | 2016 | 21 | 0.480 |
Why?
| | Evidence-Based Medicine | 2 | 2018 | 731 | 0.480 |
Why?
| | Bariatric Surgery | 1 | 2020 | 250 | 0.470 |
Why?
| | Sex Cord-Gonadal Stromal Tumors | 1 | 2015 | 5 | 0.460 |
Why?
| | Cause of Death | 2 | 2023 | 456 | 0.450 |
Why?
| | Female | 25 | 2026 | 79499 | 0.430 |
Why?
| | Retrospective Studies | 16 | 2025 | 17438 | 0.410 |
Why?
| | Ureteral Calculi | 2 | 2025 | 15 | 0.410 |
Why?
| | Prostate | 2 | 2012 | 159 | 0.410 |
Why?
| | Lithotripsy | 2 | 2025 | 47 | 0.400 |
Why?
| | Multicenter Studies as Topic | 3 | 2026 | 417 | 0.400 |
Why?
| | Orchiectomy | 4 | 2025 | 72 | 0.380 |
Why?
| | Patient Care Team | 2 | 2018 | 701 | 0.370 |
Why?
| | Young Adult | 10 | 2026 | 14330 | 0.360 |
Why?
| | Radiotherapy | 3 | 2025 | 209 | 0.360 |
Why?
| | Pediatric Obesity | 1 | 2020 | 635 | 0.360 |
Why?
| | Incidence | 4 | 2024 | 2936 | 0.360 |
Why?
| | Tonsillectomy | 2 | 2024 | 106 | 0.350 |
Why?
| | Prognosis | 5 | 2025 | 4351 | 0.350 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2013 | 196 | 0.340 |
Why?
| | Treatment Outcome | 10 | 2025 | 11821 | 0.340 |
Why?
| | Azasteroids | 1 | 2011 | 5 | 0.330 |
Why?
| | 5-alpha Reductase Inhibitors | 1 | 2011 | 16 | 0.330 |
Why?
| | Infant | 6 | 2026 | 10114 | 0.330 |
Why?
| | Referral and Consultation | 1 | 2017 | 881 | 0.320 |
Why?
| | Anticarcinogenic Agents | 1 | 2011 | 63 | 0.320 |
Why?
| | Disease Progression | 4 | 2015 | 2867 | 0.310 |
Why?
| | Kidney Neoplasms | 3 | 2019 | 419 | 0.310 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2024 | 300 | 0.300 |
Why?
| | Registries | 1 | 2018 | 2400 | 0.280 |
Why?
| | Risk Assessment | 4 | 2024 | 3712 | 0.280 |
Why?
| | Follow-Up Studies | 5 | 2025 | 5439 | 0.280 |
Why?
| | Wilms Tumor | 2 | 2019 | 91 | 0.270 |
Why?
| | Neoplasm Staging | 4 | 2016 | 1488 | 0.270 |
Why?
| | Early Detection of Cancer | 2 | 2011 | 506 | 0.250 |
Why?
| | Adenoidectomy | 2 | 2024 | 82 | 0.240 |
Why?
| | Urinary Catheterization | 1 | 2026 | 35 | 0.230 |
Why?
| | Sex Factors | 2 | 2025 | 2107 | 0.230 |
Why?
| | Pelvic Neoplasms | 1 | 2025 | 24 | 0.230 |
Why?
| | Antineoplastic Agents | 3 | 2012 | 2219 | 0.230 |
Why?
| | Nephrolithotomy, Percutaneous | 1 | 2025 | 5 | 0.220 |
Why?
| | Spermatic Cord Torsion | 1 | 2025 | 7 | 0.220 |
Why?
| | Urinary Tract | 1 | 2025 | 47 | 0.220 |
Why?
| | Case-Control Studies | 3 | 2023 | 3647 | 0.210 |
Why?
| | Fecal Incontinence | 1 | 2025 | 90 | 0.210 |
Why?
| | Fractures, Bone | 1 | 2009 | 436 | 0.200 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2026 | 1763 | 0.200 |
Why?
| | Nephrocalcinosis | 1 | 2023 | 12 | 0.200 |
Why?
| | Nephrolithiasis | 1 | 2023 | 10 | 0.200 |
Why?
| | Neoplasm Metastasis | 2 | 2016 | 693 | 0.190 |
Why?
| | Risk Factors | 4 | 2025 | 10921 | 0.180 |
Why?
| | Analgesia, Epidural | 1 | 2022 | 38 | 0.180 |
Why?
| | Meningomyelocele | 1 | 2023 | 63 | 0.180 |
Why?
| | Pilot Projects | 2 | 2025 | 1888 | 0.180 |
Why?
| | Survival Analysis | 2 | 2016 | 1378 | 0.170 |
Why?
| | Hydrocephalus | 1 | 2023 | 115 | 0.170 |
Why?
| | Double-Blind Method | 1 | 2026 | 2070 | 0.170 |
Why?
| | Spinal Cord Injuries | 1 | 2025 | 238 | 0.170 |
Why?
| | Stents | 2 | 2023 | 554 | 0.170 |
Why?
| | Device Removal | 1 | 2022 | 149 | 0.160 |
Why?
| | Cohort Studies | 2 | 2024 | 6077 | 0.160 |
Why?
| | RANK Ligand | 2 | 2010 | 29 | 0.160 |
Why?
| | Diphosphonates | 2 | 2011 | 68 | 0.160 |
Why?
| | Anastomosis, Surgical | 1 | 2020 | 164 | 0.150 |
Why?
| | Surveys and Questionnaires | 5 | 2025 | 6073 | 0.150 |
Why?
| | Combined Modality Therapy | 2 | 2014 | 1271 | 0.150 |
Why?
| | Age Factors | 2 | 2018 | 3347 | 0.150 |
Why?
| | Sex-Determining Region Y Protein | 1 | 2019 | 7 | 0.150 |
Why?
| | WT1 Proteins | 1 | 2019 | 12 | 0.150 |
Why?
| | Emotions | 1 | 2024 | 559 | 0.140 |
Why?
| | Nephrotic Syndrome | 1 | 2019 | 44 | 0.140 |
Why?
| | Disorders of Sex Development | 1 | 2019 | 40 | 0.140 |
Why?
| | Urethral Neoplasms | 1 | 2018 | 3 | 0.140 |
Why?
| | Hypertension, Renal | 1 | 2018 | 15 | 0.140 |
Why?
| | Urethral Obstruction | 1 | 2018 | 7 | 0.140 |
Why?
| | Paraganglioma, Extra-Adrenal | 1 | 2018 | 10 | 0.140 |
Why?
| | Polyps | 1 | 2018 | 13 | 0.140 |
Why?
| | Renal Artery Obstruction | 1 | 2018 | 30 | 0.140 |
Why?
| | Caregivers | 2 | 2024 | 1080 | 0.130 |
Why?
| | Urethra | 1 | 2018 | 55 | 0.130 |
Why?
| | Prenatal Diagnosis | 1 | 2019 | 190 | 0.130 |
Why?
| | Magnetic Resonance Imaging | 3 | 2019 | 3926 | 0.130 |
Why?
| | Intestines | 1 | 2020 | 351 | 0.130 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 589 | 0.130 |
Why?
| | Practice Guidelines as Topic | 2 | 2018 | 1591 | 0.130 |
Why?
| | Men's Health | 1 | 2017 | 6 | 0.130 |
Why?
| | Organ Size | 1 | 2018 | 465 | 0.130 |
Why?
| | Review Literature as Topic | 1 | 2017 | 53 | 0.120 |
Why?
| | Decision Making | 1 | 2024 | 993 | 0.120 |
Why?
| | Postoperative Period | 1 | 2018 | 355 | 0.120 |
Why?
| | Pain Management | 1 | 2020 | 421 | 0.120 |
Why?
| | Adult | 8 | 2024 | 41087 | 0.120 |
Why?
| | Tertiary Care Centers | 1 | 2017 | 196 | 0.120 |
Why?
| | Immunotherapy | 2 | 2011 | 671 | 0.120 |
Why?
| | Quality Improvement | 1 | 2025 | 1354 | 0.120 |
Why?
| | Feminization | 1 | 2015 | 6 | 0.120 |
Why?
| | Mitotic Index | 1 | 2015 | 24 | 0.120 |
Why?
| | Databases, Factual | 2 | 2022 | 1493 | 0.110 |
Why?
| | Intermittent Urethral Catheterization | 1 | 2015 | 4 | 0.110 |
Why?
| | Urination Disorders | 1 | 2015 | 15 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1064 | 0.110 |
Why?
| | Ultrasonography | 3 | 2019 | 788 | 0.110 |
Why?
| | Cloaca | 1 | 2015 | 52 | 0.110 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 504 | 0.110 |
Why?
| | Disease-Free Survival | 1 | 2016 | 778 | 0.100 |
Why?
| | Colorectal Neoplasms | 1 | 2022 | 874 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 970 | 0.100 |
Why?
| | Antibodies, Monoclonal | 2 | 2011 | 1512 | 0.100 |
Why?
| | Patient Reported Outcome Measures | 1 | 2018 | 516 | 0.100 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2018 | 778 | 0.100 |
Why?
| | Self Report | 1 | 2018 | 870 | 0.100 |
Why?
| | Creatinine | 1 | 2015 | 511 | 0.100 |
Why?
| | Infant, Newborn | 4 | 2019 | 6460 | 0.090 |
Why?
| | Estrogens | 1 | 2015 | 364 | 0.090 |
Why?
| | Radiation-Protective Agents | 1 | 2012 | 16 | 0.090 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1543 | 0.090 |
Why?
| | Metalloporphyrins | 1 | 2012 | 62 | 0.090 |
Why?
| | Alpha Particles | 1 | 2011 | 1 | 0.090 |
Why?
| | Beta Particles | 1 | 2011 | 1 | 0.090 |
Why?
| | Drug Design | 1 | 2013 | 180 | 0.090 |
Why?
| | Quality of Life | 2 | 2018 | 3200 | 0.090 |
Why?
| | Telemedicine | 1 | 2021 | 966 | 0.090 |
Why?
| | Endothelin A Receptor Antagonists | 1 | 2011 | 24 | 0.090 |
Why?
| | Clusterin | 1 | 2011 | 11 | 0.090 |
Why?
| | Receptors, Androgen | 1 | 2013 | 149 | 0.090 |
Why?
| | Obesity | 1 | 2025 | 3131 | 0.090 |
Why?
| | Mitomycin | 1 | 2011 | 31 | 0.090 |
Why?
| | Blood Chemical Analysis | 1 | 2012 | 109 | 0.090 |
Why?
| | Valproic Acid | 1 | 2011 | 45 | 0.090 |
Why?
| | Drug Costs | 1 | 2012 | 116 | 0.080 |
Why?
| | Kidney | 2 | 2019 | 1498 | 0.080 |
Why?
| | Dutasteride | 1 | 2011 | 5 | 0.080 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2011 | 70 | 0.080 |
Why?
| | United States | 4 | 2025 | 16136 | 0.080 |
Why?
| | Logistic Models | 1 | 2016 | 2126 | 0.080 |
Why?
| | Androstenols | 1 | 2010 | 4 | 0.080 |
Why?
| | Tissue Extracts | 1 | 2010 | 19 | 0.080 |
Why?
| | Denosumab | 1 | 2010 | 10 | 0.080 |
Why?
| | Bone Density Conservation Agents | 1 | 2011 | 83 | 0.080 |
Why?
| | Prostatic Hyperplasia | 1 | 2011 | 40 | 0.080 |
Why?
| | Androstenes | 1 | 2010 | 16 | 0.080 |
Why?
| | Dihydrotestosterone | 1 | 2011 | 40 | 0.080 |
Why?
| | Patient Care Management | 1 | 2011 | 54 | 0.080 |
Why?
| | Antigens, Neoplasm | 1 | 2012 | 271 | 0.080 |
Why?
| | Phenylthiohydantoin | 1 | 2010 | 44 | 0.080 |
Why?
| | Imaging, Three-Dimensional | 2 | 2012 | 582 | 0.080 |
Why?
| | Guideline Adherence | 1 | 2015 | 594 | 0.080 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2011 | 141 | 0.080 |
Why?
| | Taxoids | 1 | 2010 | 115 | 0.080 |
Why?
| | Longitudinal Studies | 1 | 2018 | 3017 | 0.080 |
Why?
| | Ultrasound, High-Intensity Focused, Transrectal | 1 | 2010 | 2 | 0.080 |
Why?
| | Biomedical Research | 1 | 2017 | 729 | 0.080 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2011 | 219 | 0.080 |
Why?
| | Hormone Antagonists | 1 | 2009 | 32 | 0.080 |
Why?
| | Benzamides | 1 | 2010 | 226 | 0.070 |
Why?
| | Cost-Benefit Analysis | 1 | 2012 | 640 | 0.070 |
Why?
| | Nitriles | 1 | 2010 | 212 | 0.070 |
Why?
| | Bone Remodeling | 1 | 2009 | 71 | 0.070 |
Why?
| | Mobility Limitation | 1 | 2009 | 68 | 0.070 |
Why?
| | Risk | 1 | 2011 | 920 | 0.070 |
Why?
| | Collagen Type I | 1 | 2009 | 144 | 0.070 |
Why?
| | Antioxidants | 1 | 2012 | 544 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2011 | 298 | 0.070 |
Why?
| | Mutation | 1 | 2019 | 4093 | 0.070 |
Why?
| | Middle Aged | 6 | 2016 | 36619 | 0.060 |
Why?
| | Aged | 4 | 2016 | 26432 | 0.060 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2013 | 893 | 0.060 |
Why?
| | Biomarkers, Tumor | 1 | 2014 | 1339 | 0.060 |
Why?
| | Computer Simulation | 1 | 2011 | 1014 | 0.060 |
Why?
| | Software | 1 | 2011 | 676 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 983 | 0.050 |
Why?
| | Clinical Protocols | 1 | 2026 | 282 | 0.050 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 992 | 0.050 |
Why?
| | Calcium Oxalate | 1 | 2023 | 7 | 0.050 |
Why?
| | Canada | 1 | 2025 | 432 | 0.050 |
Why?
| | Peptides | 1 | 2009 | 992 | 0.050 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2024 | 82 | 0.050 |
Why?
| | Mass Screening | 1 | 2011 | 1307 | 0.050 |
Why?
| | Polysomnography | 1 | 2024 | 239 | 0.050 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 2023 | 44 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2022 | 2113 | 0.050 |
Why?
| | Colostomy | 1 | 2022 | 28 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 1998 | 0.040 |
Why?
| | Morphine | 1 | 2022 | 171 | 0.040 |
Why?
| | Animals | 3 | 2013 | 38107 | 0.040 |
Why?
| | Urologists | 1 | 2021 | 20 | 0.040 |
Why?
| | Internship and Residency | 1 | 2011 | 1281 | 0.040 |
Why?
| | Signal Transduction | 1 | 2013 | 5246 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2023 | 1135 | 0.040 |
Why?
| | Cytoskeletal Proteins | 1 | 2019 | 146 | 0.040 |
Why?
| | Consensus | 1 | 2021 | 467 | 0.040 |
Why?
| | Metanephrine | 1 | 2018 | 4 | 0.030 |
Why?
| | Normetanephrine | 1 | 2018 | 4 | 0.030 |
Why?
| | Cystography | 1 | 2018 | 3 | 0.030 |
Why?
| | Renin | 1 | 2018 | 33 | 0.030 |
Why?
| | Patient Readmission | 1 | 2024 | 778 | 0.030 |
Why?
| | Urinary Retention | 1 | 2018 | 23 | 0.030 |
Why?
| | Lymph Node Excision | 1 | 2019 | 174 | 0.030 |
Why?
| | Oxygen | 1 | 2023 | 997 | 0.030 |
Why?
| | Nephrectomy | 1 | 2019 | 172 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2019 | 429 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2019 | 410 | 0.030 |
Why?
| | Norepinephrine | 1 | 2018 | 201 | 0.030 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 195 | 0.030 |
Why?
| | Epithelium | 1 | 2018 | 295 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2021 | 706 | 0.030 |
Why?
| | Global Burden of Disease | 1 | 2017 | 25 | 0.030 |
Why?
| | Urologic Neoplasms | 1 | 2017 | 31 | 0.030 |
Why?
| | Computed Tomography Angiography | 1 | 2018 | 151 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2017 | 122 | 0.030 |
Why?
| | Infertility, Male | 1 | 2017 | 69 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 429 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 426 | 0.030 |
Why?
| | Genetic Testing | 1 | 2019 | 492 | 0.030 |
Why?
| | Endoscopy | 1 | 2018 | 316 | 0.030 |
Why?
| | Urinary Diversion | 1 | 2015 | 15 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2015 | 156 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1503 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1707 | 0.020 |
Why?
| | Image-Guided Biopsy | 1 | 2012 | 41 | 0.020 |
Why?
| | Penis | 1 | 2012 | 33 | 0.020 |
Why?
| | Erectile Dysfunction | 1 | 2012 | 35 | 0.020 |
Why?
| | Prostatectomy | 1 | 2012 | 93 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2012 | 84 | 0.020 |
Why?
| | Testis | 1 | 2012 | 158 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2012 | 313 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2015 | 745 | 0.020 |
Why?
| | Drug Synergism | 1 | 2011 | 354 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2011 | 183 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5899 | 0.020 |
Why?
| | Efficiency | 1 | 2011 | 102 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2023 | 2363 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2011 | 882 | 0.020 |
Why?
| | Reference Values | 1 | 2011 | 796 | 0.020 |
Why?
| | DNA Damage | 1 | 2012 | 439 | 0.020 |
Why?
| | Workload | 1 | 2011 | 170 | 0.020 |
Why?
| | Safety | 1 | 2011 | 347 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1036 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 2786 | 0.020 |
Why?
| | Skin | 1 | 2012 | 701 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2012 | 2537 | 0.020 |
Why?
| | Pregnancy | 1 | 2019 | 7230 | 0.010 |
Why?
| | Time Factors | 1 | 2017 | 7109 | 0.010 |
Why?
| | Models, Biological | 1 | 2012 | 1761 | 0.010 |
Why?
| | Rats | 1 | 2012 | 5586 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2011 | 3416 | 0.010 |
Why?
|
|
Rove's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|